AL01211 from AceLink Therapeutics is a glucosylceramide synthase (GCS) inhibitor that completed Phase 1 in healthy volunteers. No Phase 2 has been registered.
Background
Glucosylceramide synthase (GCS) inhibitors target sphingolipid metabolism, which plays a role in cyst formation and growth. AL01211 was developed by AceLink Therapeutics in China and tested in a first-in-human study of 69 healthy volunteers. The Phase 1 study was completed in June 2022.
How It Works
GCS catalyzes the first step in the synthesis of glycosphingolipids. In PKD, abnormal accumulation of glucosylceramide (GL-1) in kidney cells promotes cyst growth. By inhibiting GCS, AL01211 aims to reduce GL-1 levels and slow cyst cell proliferation. This is the same pathway targeted by Sanofi's venglustat, which showed disappointing Phase 2/3 results in a related kidney disease (Fabry), raising questions about the approach.
Clinical Trial Details
The Phase 1 study (NCT04908462) enrolled 69 healthy volunteers in China. It was a standard dose-escalation safety study. Results have not been publicly published, and no Phase 2 trial for ADPKD has been registered as of mid-2026.
Why It's Promising
If the GCS pathway proves relevant in ADPKD (distinct from its role in Fabry disease), this oral small molecule could offer a well-tolerated option. However, the lack of follow-up activity since 2022 is concerning.
Limitations & Concerns
No published Phase 1 results. No Phase 2 registered after 4 years. The GCS inhibitor class had setbacks in related diseases. The development program may have stalled.